Safety of Once-Daily Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol in Japanese Patients with Asthma: A Long-Term (52-Week) Phase III Open-Label Study

PURPOSE: The pivotal CAPTAIN study reported a favorable safety profile with once-daily inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β(2)-agonist (ICS/LAMA/LABA) triple combination of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with inadequately contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hozawa, Soichiro, Ohbayashi, Hiroyuki, Tsuchiya, Michiko, Hara, Yu, Lee, Laurie A, Nakayama, Takashi, Tamaoki, Jun, Fowler, Andrew, Nishi, Takanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275015/
https://www.ncbi.nlm.nih.gov/pubmed/34262299
http://dx.doi.org/10.2147/JAA.S305918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275015/
https://www.ncbi.nlm.nih.gov/pubmed/34262299
http://dx.doi.org/10.2147/JAA.S305918

Ejemplares similares